ERBB2 and breast carcinoma: As compared to the Her2‐positive breast cancer cell lines (MDA‐MB‐453, SK‐BR‐3), TNBCs (MDA‐MB‐231, MDA‐MB‐468), are the most aggressive ones due to the absence of targeted therapies in contrast to the luminal breast cancer cell lines (MCF‐7, BT‐474).2, 32